In response to concerns about the sustainability of US drug-development efforts, FDA has released a report, titled Driving Biomedical Innovation: Initiatives to Improve Products for Patients. The report outlines several steps that FDA will take to spur biomedical innovation and ensure that such innovation can be quickly translated into safe and effective therapies. Input used to compile the report was obtained from a broad spectrum of stakeholders, including members of large pharmaceutical companies, small biotech companies, academic researchers, and patient advocacy groups.
The report outlines major areas in which FDA will be launching initiatives to address feedback obtained from stakeholders. They include:
- Rebuilding FDA’s small business outreach services: FDA will establish a FDA Small Business Liaison program and a Young Entrepreneurs program, as well as establish a new partnership with the US Small Business Administration.
To read the full, original article click on this link: FDA Outlines Strategy to Spur Biomedical Innovation - Pharmaceutical Technology
Author:Amy Ritter
